Versant Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Versant Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.79K	Buy	128 +9	+8%	+$335	﹤0.01%	2439
2026 Q1	$4.32K	Buy	119 +15	+14%	+$670	﹤0.01%	2421
2025 Q4	$4.84K	Hold	104	–	–	﹤0.01%	2263
2025 Q3	$4.33K	Sell	104 -1,224	-92%	-$39.1K	﹤0.01%	2261
2025 Q2	$38.2K	Buy	1,328 +1,238	+1,376%	+$38.2K	0.01%	1135
2025 Q1	$3.02K	Buy	+90	New	+$3.36K	﹤0.01%	2198
2023 Q3	–	Sell	-31	Closed	-$559	–	1958
2023 Q2	$559	Buy	+31	New	+$618	﹤0.01%	1809

Other funds holding CRNX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

PAS

Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Versant Capital Management's CRNX Position: Q2 2026 in Review

Versant Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 7.6% in Q2 2026, buying an estimated $335 and bringing the position to 128 shares worth $4.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Versant Capital Management first reported a position in CRNX in Q2 2023 and has held it in 7 quarters since. The position peaked at $38.2K in Q2 2025. 19 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Versant Capital Management held 128 shares of Crinetics Pharmaceuticals worth $4.79K as of Q2 2026.
Versant Capital Management bought 9 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $335.
Crinetics Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2439 holding.
Versant Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
Versant Capital Management's Crinetics Pharmaceuticals position peaked at $38.2K in Q2 2025.
19 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.